ODE Pharma

ODE Pharma Overview

ODE Pharma is a pioneering biotechnology company at the forefront of developing innovative treatments for respiratory and pulmonary disorders. By harnessing the power of the body’s natural systems, specifically the gut microbiome and mitochondria, the company is driving advancements in healthcare and improving patient outcomes. ODE Pharma is currently developing ODE-001 that potentially enables cell restoration and regeneration, strengthens cells and reduces inflammation. ODE-001 has the potential to be indicated for the treatment of multiple respiratory and gastrointestinal diseases. By providing a required biochemical component to the cells’ powerhouses, and augmenting regulatory programs, ODE-001 renews and allows organs to survive longer and pass the organs’ failure breaking point.

Latest News

Aug 26, 2024 · nocamels.com

growth-positive

Startup Sees Potential Of Papaya To Treat Cystic Fibrosis In Kids

ODE Pharma, an Israeli biotech startup, is developing a novel treatment for cystic fibrosis and other respiratory disorders using a molecule derived from papaya. The company has raised $1.5 million and is seeking an additional $5 million in funding. ODE Pharmas molecule, ODE-001, has shown promising results in clinical trials, significantly improving outcomes for COVID-19 patients. The company plans to start clinical trials for cystic fibrosis treatment in children and aims to release the molecule as a supplement for respiratory issues. ODE is partnering with Catalent for mass production of the supplement. The investment is backed by the Pollen Innovation Group.

InvestmentPartnersCustomers

Funding

Team Members

1

Employees: 1-10

Web & Social Links

Locations

Jerusalem, Israel

Photos & Videos

No files yet

ODE Pharma Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info